New hope for leukemia patients: asciminib study launches in china
NCT ID NCT07375355
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study looks at how well and how safely the drug asciminib works for people in China who have just been diagnosed with chronic myeloid leukemia in its early phase. About 200 adults will take the drug and be followed for at least 12 months to see if their cancer cells drop to very low levels. The goal is to control the disease long-term, not to cure it, since ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.